Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
Evans
W E
WE
Department of Pharmaceutical Sciences and Hematology-Oncology, St. Jude Children's Research Hospital, University of Tennessee, Colleges of Pharmacy and Medicine, Memphis 38105, USA.
Pui
C H
CH
Relling
M V
MV
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011003:Ploidies; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate